Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Sint-Martens-Latem – page 106

1 432 clinical trials in Sint-Martens-Latem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Sint-Martens-Latem at a glance
1 432
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 432 trials in Sint-Martens-Latem

Open in trial search

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Belzutifan for Patients with Advanced Kidney Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Study on Fluid Therapy and Noradrenaline for Low Blood Pressure in Breast Reconstruction Surgery Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Potassium Chloride
  • Sponsor:Az Maria Middelares Gent

Follicular lymphoma+2

Not recruiting

Study Comparing Odronextamab and Lenalidomide with Rituximab and Lenalidomide for Patients with Relapsed/Refractory Follicular and Marginal Zone Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Regeneron Pharmaceuticals Inc.

Cystic fibrosis

Not recruiting

Study on VX-522 and Ivacaftor for Adults with Cystic Fibrosis Unresponsive to CFTR Modulator Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Neoplasm malignant

Not recruiting

Study on the Long-Term Safety of Sacituzumab Govitecan for Patients with Metastatic Solid Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Gilead Sciences Inc.

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of BLU-222 Alone and with Drug Combination for Patients with Advanced Solid Tumors, Including Breast and Ovarian Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BLU-222
  • Sponsor:Blueprint Medicines Corp.

Study of Atezolizumab, Bevacizumab, and Tiragolumab for Patients with Untreated Advanced or Metastatic Liver Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Hidradenitis

Not recruiting

Study on Upadacitinib for Adults and Adolescents with Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on Reduced Antiplatelet Therapy with Acetylsalicylic Acid and Clopidogrel for Patients with Coronary Artery Disease After Stent Implantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Ivascular S.L.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Sint-Martens-Latem

What the registry says about research in the country

01 Musculoskeletal Diseases

Clinical research in Sint-Martens-Latem is focused on musculoskeletal diseases, with a strong emphasis on osteoarthritis and related joint pain. The studies are designed to better understand treatment options that may improve comfort and day-to-day function.

  • Knee osteoarthritis
  • Osteoarthritis
  • Testing new approaches to ease joint pain and support mobility

These trials aim to assess whether emerging therapies can offer meaningful relief for people living with chronic joint disease.

02 Nutritional and Metabolic Diseases

Another active area is nutritional and metabolic diseases, especially studies involving overweight and obesity. Research here is exploring whether new treatments can help with weight management while also addressing related health concerns.

  • Overweight or obesity
  • Evaluating therapies that may support healthier body weight
  • Looking at how metabolic treatment options may affect symptoms linked to joint disease

In addition to weight-related outcomes, the research also considers how these approaches may influence overall well-being in people with overlapping conditions.

03 Combined Osteoarthritis and Weight-Related Research

The clinical trial landscape also brings together osteoarthritis and obesity research, reflecting the close connection between excess body weight and knee pain. This combined focus is especially relevant for patients whose symptoms are affected by both joint and metabolic factors.

  • Knee osteoarthritis with overweight or obesity
  • Measuring changes in pain and physical comfort
  • Assessing whether a new therapy can support both symptom relief and weight-related outcomes

These studies aim to generate practical evidence on treatments that may address more than one aspect of the condition at the same time.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.